What is it about?
Embryonal tumor with multilayered rosettes (ETMR) is a rare pediatric brain tumor with increased malignant potential. Despite the advances in treatment schemes, the overall 5-year survival for these tumors is not favorable. We report one patient with refractory ETMR who was successfully treated by implementing a molecular profiling approach which identified the tyrosine kinase inhibitor dasatinib as a viable therapy. Our results suggest that utilizing this precision medicine approach might prove useful in treating patients with refractory ETMR.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
The treatment regimes for refractory ETMR are restricted to a case-by-case basis due to the limited amount of literature and guidelines available for treating childhood ETMR. Here we report the successful use of molecular individualized profiling and dasatinib therapy in the treatment of a 32-month-old patient with ETMR for whom standard therapy had failed.
Perspectives
Our results suggest that utilizing this precision medicine approach might prove useful in treating patients with refractory ETMR. Following this clinical case was very gratifying because until now the patient remains disease-free with no evidence of recurrent tumor.
Elisa Robles
University of Texas at El Paso
Read the Original
This page is a summary of: Integration of a Personalized Molecular Targeted Therapy into the Multimodal Treatment of Refractory Childhood Embryonal Tumor with Multilayered Rosettes (ETMR), Case Reports in Oncology, February 2019, Karger Publishers,
DOI: 10.1159/000497380.
You can read the full text:
Contributors
The following have contributed to this page
